Caleb Rans, PharmD

Investigators found data that showed upadacitinib improved patient-reported outcomes.

Researchers found data that showed the use of the biosimilar infliximab resulted in appreciable cost savings compared with golimumab in the treatment of rheumatoid arthritis.

Researchers found data that showed an association between the development of rheumatoid arthritis and exposure to animal dust in both men and women, but in women there was a risk associated with textile dust.

Improvement is needed in shared decision-making in the treatment of RA, according to researchers in The Netherlands.

Investigators found data that showed the superiority of sarilumab monotherapy over adalimumab in both clinical and functional domains.

Researchers found data that showed using the semiquantitative ultrasound score in the assessment of finger joint cartilage damage caused by rheumatoid arthritis is effective.

Investigators found data that showed magnetic resonance imaging measurements might predict treatment response in rheumatoid arthritis.

Researchers compared effectiveness of certolizumab pegol plus conventional synthetic DMARDs in patients with rheumatoid arthritis, followed by continuing vs discontinuing background csDMARDs after treatment response.

Twelve weeks of lovastatin in patients with mildly active RA had no adjunctive therapeutic effects.

Education about taking medication during pregnancy is needed to better support decisions among women with rheumatoid arthritis.

Researchers retrospectively studied pregnant women with rheumatoid arthritis who were treated with oral corticosteroids.

Although MRI-detected tenosynovitis was associated with inflammatory arthritis development, the addition of foot MRI to hand MRI did not increase the predictive accuracy.

A possible immunologic response from antibiotic use is posited by researchers as a risk factor for rheumatoid arthritis.

Investigators observed that many patients with moderate or high rheumatoid arthritis activity are resistant to changing their treatment to achieve remission or low disease activity and sought to determine why.

Researchers found data that showed that more than half of patient global assessment scores emphasized pain and the ability to function daily, rather than emotional distress, for patients with rheumatoid arthritis.

In The Netherlands, researchers found data that revealed no long-term benefits of an intensive disease activity score steered treatment regimen vs routine care to achieve disease-modifying antirheumatic drug-free sustained remission in patients with rheumatoid arthritis.

In Japan, researchers found data from a large phase 3 study that showed combined conventional synthetic disease-modifying antirheumatic drugs and denosumab therapy was found to significantly inhibit the progression of joint destruction in patients with rheumatoid arthritis.

Researchers in The Netherlands found data from a study period of 23 years that showed combination therapy with sulfasalazine and methotrexate was effective for disease control and fewer adverse events, when compared with monotherapy with sulfasalazine.

Researchers found that there was no difference in the incidence of malignancy in patients with rheumatoid arthritis who switched from biologic disease-modifying antirheumatic drugs or tofacitinib to tocilizumab compared with patients who used abatacept or a different tumor necrosis factor inhibitor, except in instances of nonmelanoma skin cancer.